Intracranial Pressure (ICP) Monitoring Devices Market Size, Share, Growth, and Industry Analysis, By Type (Invasive ICP Devices,Non-invasive ICP Devices), By Application (Traumatic Brain Injury,Intracerebral Hemorrhage,Meningitis,Subarachnoid Hemorrhage,Others), Regional Insights and Forecast to 2035

Intracranial Pressure (ICP) Monitoring Devices Market Overview

Global Intracranial Pressure (ICP) Monitoring Devices Market valued at USD 564.56 Million in 2026, projected to reach USD 944.38 Million by 2035, growing at a CAGR of 5.88%.

The global Intracranial Pressure (ICP) Monitoring Devices Market comprises device shipments estimated at over 310,000 units in 2023 across hospitals, clinics, and trauma centers. The installed base of invasive and non‑invasive systems reached approximately 285,000 systems worldwide by end‑2024. The invasive technique segment accounted for roughly 80–94 percent of unit share in 2024–2025. Non‑invasive systems comprised around 6–20 percent of total device units. Hospitals represented over 50 percent of end‑user installations in 2023. These numbers underpin the Intracranial Pressure (ICP) Monitoring Devices Market Report, Intracranial Pressure (ICP) Monitoring Devices Market Analysis, Intracranial Pressure (ICP) Monitoring Devices Market Research Report and Intracranial Pressure (ICP) Monitoring Devices Industry Report.

In the USA Intracranial Pressure (ICP) Monitoring Devices Market, device unit consumption reached approximately 90,000 units during 2023, representing about 31 percent of global system shipments. Installed base in US hospitals and trauma centres exceeded 95,000 systems by end‑2023. The invasive technique accounted for circa 79 percent share of U.S. systems in 2023. Annual U.S. traumatic brain injuries numbered around 1,000,000 cases, with 230,000 hospitalisations, 50,000 deaths, and 80,000–90,000 long‑term disabilities, driving device uptake. Stroke cases totaled roughly 795,000 incidents, and migraine sufferers numbered about 35,000,000 individuals, contributing to demand. This underscores the Intracranial Pressure (ICP) Monitoring Devices Market Size, Intracranial Pressure (ICP) Monitoring Devices Market Trends, Intracranial Pressure (ICP) Monitoring Devices Market Insights.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: traumatic brain injury incidence 26 percent share; stroke and hydrocephalus 38.6 percent of application units.
• Major Market Restraint: non‑invasive adoption remains low at 6–20 percent of total units deployed.
• Emerging Trends: wireless micro‑sensor use nearly 51 percent of hospital installations in 2024–
• Regional Leadership: North America held 38 percent share of device units in 2024; U.S. 95 percent of North America units.
• Competitive Landscape: invasive segment share 80.1 percent globally in 2024; major players account for 60 percent of unit shipments.
• Market Segmentation: invasive devices 80–94 percent share of units; non‑invasive 6–20 
• Recent Development: invasive share expected to reach 94.2 percent by 2037 in product segmentation. (each with percent‑wise data)

Intracranial Pressure (ICP) Monitoring Devices Market Latest Trends

The Intracranial Pressure (ICP) Monitoring Devices Market Trends show rapid uptake of wireless micro‑sensor devices, with over 51 percent of all hospital ICP installations in 2024 embracing minimally invasive platforms. Invasive catheters and transducers maintained unit share of 80–94 percent, while non‑invasive Doppler, optic nerve sheath diameter and tympanic displacement devices accounted for 6–20 percent of total units. The Traumatic Brain Injury application segment held approximately 38–39 percent share of devices in 2025. Non‑invasive adoption rose to 7 percent share of units in Asia‑Pacific in 2024. North America maintained device unit share of 38 percent globally in 2024, Asia‑Pacific captured about 25 percent, Europe about 30 percent, and Middle East & Africa about 7 percent. Hospitals and trauma centres comprised over 50 percent of installations, clinics around 30 percent, and neurosurgery centres roughly 20 percent. Telerobotic telesensor use reduced inpatient neurosurgical procedures by approximately £5236 savings per patient in a matched‑pair study of 48 pairs. Device accuracy within 1.0 mm Hg versus traditional invasive systems was reported in over 75 percent of clinical trials using predictive analytic platforms.

Intracranial Pressure (ICP) Monitoring Devices Market Dynamics

DRIVER

"Rising incidence of neurological disorders and TBI"

In 2023, over 1,000,000 U.S. traumatic brain injuries occurred, with 230,000 hospitalisations, 50,000 deaths, and 80,000–90,000 long‑term disabilities. Worldwide, an estimated 7.6 million ischemic strokes occurred annually, plus 6.5 million unruptured brain aneurysms and 30,000 ruptures in the U.S. Driving factors include TBI incidence 1 million per year in the U.S., stroke 795,000 incidents, migraine 35 million sufferers, hydrocephalus case load rising, leading to demand for ICP devices in hospitals (> 50 percent of installations). Increasing unit shipments reached over 310,000 globally in 2023 and approx 285,000 systems installed by end‑2024. These real numbers reinforce how the driver high prevalence of neurological disorders fuels unit consumption in the market.

RESTRAINT

"Limited adoption of non""‑invasive devices"

The non‑invasive technique segment accounted for only around 6–20 percent of total device units by 2024. In North America, non‑invasive device share remained near 10 percent of installed systems. Adoption lags due to accuracy concerns, with invasive systems still dominant at 80–94 percent of unit share. Quality control issues such as zero pressure drift and signal quality affect non‑invasive uptake. Sensor drift in implantable transducers remains a challenge in roughly 15–20 percent of monitoring cases. In some clinical guidelines, up to 50 percent of TBI patients eligible for invasive monitoring never receive devices, limiting broader penetration. Overall, this restraint reduces demand for non‑invasive product units in hospitals and trauma centres.

OPPORTUNITY

"Growth in wireless micro""‑sensor and telesensor deployment"

Wireless micro‑sensor systems comprised over 51 percent of hospital device installations in 2024. Telesensor patients showed cost‑saving of approx £5236 per matched pair over two years, with 136 patients monitored. These innovations reduce radiographic encounters by around 30 percent and neurosurgical inpatient admissions by comparable percentages. Asia‑Pacific non‑invasive unit share rose to 7 percent in 2024. The invasive segment’s share is forecast to reach 94.2 percent by 2037 in device units, enabling hybrid deployment of advanced minimally invasive platforms. This represents tangible investment prospects for hospitals, device OEMs and B2B buyers in the Intracranial Pressure (ICP) Monitoring Devices Market Forecast and Market Opportunities.

CHALLENGE

"Skilled operator shortages and procedural variability"

Roughly 50 percent of patients meeting invasive ICP monitoring criteria never receive devices, due to clinician variability and training gaps. Procedural complications bleeding rates up to 5 percent in implantation create hesitancy. In invasive systems, sensor drift affects mean ICP indices in up to 15–20 percent of signals. In non‑invasive approaches, quality control issues lead to device rejection in approximately 10 percent of measurement attempts. Variations in ICP guideline adherence across centers uptake varying ±50 percent limit consistent deployment. These challenges hamper broader adoption of both invasive and non‑invasive units in hospitals and trauma centers in the Intracranial Pressure (ICP) Monitoring Devices Market Industry Analysis.

Intracranial Pressure (ICP) Monitoring Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Intracranial Pressure (ICP) Monitoring Devices Market Segmentation by type and application divides units by two principal technique types and five application categories. Invasive ICP devices comprised approximately 80–94 percent of units globally by 2024 and non‑invasive units about 6–20 percent. Application segmentation units: Traumatic Brain Injury around 38–39 percent, Intracerebral Hemorrhage and Subarachnoid Hemorrhage collectively 25 percent, Meningitis and Others combined 37 percent.

BY TYPE

Invasive ICP Devices: Invasive ICP devices external ventricular drains and microtransducer catheters comprised roughly 80–94 percent share of device unit installations by 2024. External Ventricular Drainage units represented approximately 60 percent of invasive shipments, microtransducer systems roughly 40 percent. Accuracy of invasive systems was within ≤ 1.0 mm Hg in over 75 percent of clinical validation studies. Guideline‑based use occurred in approximately 50 percent of severe TBI cases with Glasgow Coma Scale < 8. Invasive devices account for nearly all hospital and trauma centre installs, amounting to over 250,000 systems globally by 2023–2024.

The invasive segment is estimated to account for approximately USD 380.5 million in 2025 (71.4% share) and rise to USD 625.0 million by 2034, growing at a CAGR of 5.5% due to clinical preference in critical diagnostics.

Top 5 Major Dominant Countries in the Invasive Segment

• United States: Estimated at USD 150.4 million in 2025 (≈39.5% share), growing at 5.3% CAGR, led by neurosurgical ICU adoption.
• Germany: Valued at USD 38.1 million, capturing 10% share, with 5.6% CAGR driven by advanced neurological hospitals.
• Japan: At USD 35.4 million in 2025, 9.3% share, growing at 5.4% CAGR fueled by aging population and stroke care.
• United Kingdom: Holding USD 30.2 million (≈8%), with 5.5% CAGR supported by trauma center standards.
• India: Estimated at USD 22.8 million (6%), with 6.1% CAGR due to increasing neurosurgical infrastructure in urban hospitals.

Non‑invasive ICP Devices: Non‑invasive ICP devices including transcranial Doppler ultrasonography, optic nerve sheath diameter, tympanic membrane displacement, MRI/CT, and fundoscopy made up only 6–20 percent of device units by 2024. Transcranial Doppler constituted about 40 percent of non‑invasive shipments, optic nerve sheath 30 percent, TMD 15 percent, MRI/CT/fundoscopy 15 percent. Adoption increased moderately in Asia‑Pacific to around 7 percent of installed base in 2024. Accuracy concerns and quality control issues reduce repeat measurement success in 10 percent of cases.

The non-invasive segment is projected at USD 152.7 million in 2025 (28.6% share) and expected to reach USD 266.9 million by 2034, expanding at a 6.4% CAGR driven by non-surgical and pediatric applications.

Top 5 Major Dominant Countries in the Non‑invasive Segment

• United States: Estimated at USD 61.3 million (≈40% share), with 6.2% CAGR supported by clinical monitoring innovation.
• Germany: At USD 20.5 million, 13% share, growing at 6.5% CAGR as non-invasive monitoring gains in neuro units.
• Japan: With USD 18.9 million, (12.4% share), expanding at 6.3% CAGR due to preference for non-surgical diagnostics.
• United Kingdom: Captures USD 17.1 million (11%), growing at 6.4% CAGR amid portable monitoring adoption.
• India: Forecast to reach USD 12.5 million (8.2%), with 7.0% CAGR reflecting early-stage technology uptake in tertiary hospitals.

BY APPLICATION

Traumatic Brain Injury: Devices used in Traumatic Brain Injury (TBI) applications accounted for 38–39 percent of total device units in 2025. In the U.S., approximately 1,000,000 TBI cases per year generated 230,000 hospitalizations, 50,000 deaths, and 80,000–90,000 long‑term disabilities, leading to high ICP monitoring penetration in trauma centres. TBI devices represent the single largest application share globally. In TBI guideline‑eligible patients (GCS < 8 with abnormal CT), invasive monitoring was used in nearly 50 percent but remains underutilised.

Expected to represent approximately USD 200.6 million in 2025 (37.6% share), this segment is projected to grow at a CAGR of 6.1% by 2034 due to its critical diagnostic value in trauma centers.

Top 5 Major Dominant Countries in the Traumatic Brain Injury Application

• United States: Estimated to account for USD 72.3 million in 2025, growing at 6.0% CAGR, representing 36% global TBI device usage.
• Germany: At USD 25.7 million, 12.8% share, growing at 6.3% CAGR, driven by robust trauma systems.
• Japan: With USD 22.4 million, 11.2% share, and 6.2% CAGR based on widespread auto and fall-related injury monitoring.
• United Kingdom: Holding USD 20.8 million (≈10.4%), with 6.1% CAGR, reflecting increased TBI diagnostic protocols.
• India: Forecasted at USD 15.1 million, 7.5% share, growing at 6.6% CAGR amid expanding emergency neurocare.

Intracerebral Hemorrhage and Subarachnoid Hemorrhage: Combined, Intracerebral Hemorrhage (ICH) and Subarachnoid Hemorrhage (SAH) applications accounted for around 25 percent of device units in 2024–2025. ICH involvement accounted for about 15 percent, SAH about 10 percent. Elevated intracranial pressure in hemorrhagic stroke cases triggered installation of ICP systems in approximately 60 percent of severe cases.

This application is valued near USD 116.6 million in 2025 (21.9% share) and expected to grow at 5.8% CAGR, due to rising stroke-related hemorrhagic events and ICU monitoring.

Top 5 Major Dominant Countries in the Intracerebral Hemorrhage Application

• United States: Leads with USD 46.2 million in 2025, 39.6% share, growing at 5.7% CAGR across neuro ICU units.
• Germany: Holding USD 14.9 million (12.8% share), with 5.9% CAGR supported by stroke care infrastructure.
• Japan: With USD 12.4 million, 10.6% share, expanding at 5.8% CAGR due to aging demographics.
• United Kingdom: Estimated at USD 11.7 million, 10% share, growing at 5.8% CAGR amid care pathway improvements.
• India: Forecast at USD 9.8 million, 8.4% share, with 6.2% CAGR tied to growing stroke unit capacity.

Meningitis: Meningitis applications contributed about 5 percent of total device unit deployments. Cerebrospinal fluid pressure measurement in bacterial meningitis occasionally demanded invasive monitoring, though rare. Devices used in meningitis accounted for roughly 3,000–5,000 units globally in 2023.

Expected to be worth approximately USD 53.3 million in 2025 (10% share) and projected to grow at a 5.5% CAGR to 2034, supported by increased neuro-infectious disease surveillance.

Top 5 Major Dominant Countries in the Meningitis Application

• United States: Estimated to reach USD 19.2 million in 2025, 36% share, with 5.4% CAGR, reflecting pediatric ICU usage.
• India: At USD 8.1 million, 15.2% share, with 6.0% CAGR driven by neuro-infection protocols.
• Germany: With USD 6.9 million, 13% share, CAGR of 5.6% as adult ICU neuro-care expands.
• Japan: USD 6.3 million (12% share), growing at 5.5% CAGR, supported by hospital infection management.
• South Africa: Estimated at USD 4.2 million, 8% share, with 6.3% CAGR, reflecting neurocritical care adoption in urban centers.

Others (Hydrocephalus, Migraine, CSF Management): Others including hydrocephalus, migraine, CSF management and miscellaneous neurological conditions made up about 32–37 percent of total units. Hydrocephalus represented around 20 percent, migraine 10 percent, CSF management and other causes 7–8 percent. Migraine sufferers in the U.S. numbered about 35 million, but ICP monitoring used in only a small fraction of cases.

The Other neurological conditions category is valued at USD 51.6 million in 2025 (9.7% share) and expected to grow at 5.9% CAGR due to neuro ICU expansions beyond core ICP indications.

Top 5 Major Dominant Countries in the Others Application

• United States: Forecasted at USD 18.4 million in 2025, holding 35.7% share, with a 5.8% CAGR covering varied neurological monitoring uses.
• Germany: At USD 6.7 million, 13% share, growing at 5.9% CAGR across post-operative neuro ICU settings.
• Japan: Holding USD 6.0 million (11.6% share), with 5.7% CAGR across less common neuro-critical applications.
• India: At USD 5.1 million, 9.9% share, growing at 6.2% CAGR in emerging neuro critical care.
• United Kingdom: USD 5.0 million (9.7%), with 5.7% CAGR, reflecting mixed neuro-monitoring demand.

Intracranial Pressure (ICP) Monitoring Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounted for about 38 percent of global device units in 2024. The U.S. represented approximately 95 percent of North American installations. Device units in the U.S. numbered around 90,000 units in 2023, out of global shipments of c. 310,000. Hospitals and trauma centres in North America dominated end‑user share at over 50 percent, clinics 30 percent, neurosurgery centres 20 percent. The invasive technique held 79 percent of U.S. share in 2023. Traumatic Brain Injury applications comprised approx 38 percent; hemorrhage applications 25 percent. Non‑invasive share remained near 10 percent in North America. Wireless micro‑sensor systems constituted over 51 percent of hospital installs in 2024. These figures underpin the Intracranial Pressure (ICP) Monitoring Devices Market Outlook, Intracranial Pressure (ICP) Monitoring Devices Market Size, Intracranial Pressure (ICP) Monitoring Devices Market Opportunities.

North America is forecast to represent approximately USD 230.0 million in 2025 about 43% of the global market and is expected to grow at a CAGR of 5.6%, driven by advanced neurocritical care capabilities and aged population.

North America – Major Dominant Countries in the “ICP Monitoring Devices Market”

• United States: The U.S. ICP monitoring devices market is expected to reach USD 190.0 million by 2034, holding 82.6% of North America’s share and growing at 5.5% CAGR across major clinical settings.
• Canada: Canada’s market is projected at USD 22.5 million by 2034, accounting for 9.8% of the region with a CAGR of 5.8% driven by public health expansions.
• Mexico: Mexico’s market is likely to reach USD 12.3 million by 2034, contributing 5.3% regional share and growing at 5.7% CAGR as neurotrauma care improves.
• Cuba: Projected at USD 3.0 million by 2034, Cuba’s share is 1.3% of regional market with 5.4% CAGR from growing hospital services.
• Puerto Rico: Puerto Rico is expected to reach USD 2.2 million by 2034, capturing 0.9% regional share, with CAGR of 5.2% driven by critical care expansion.

EUROPE

In Europe, device units constituted approximately 30 percent of global installed base in 2024. Germany held the second‑largest market share in Europe, followed by the UK, France, Italy, and Spain. The invasive technique represented about 82 percent of installations; non‑invasive around 18 percent. Traumatic Brain Injury applications comprised nearly 36 percent of devices in Europe, hemorrhage applications 24 percent, others 40 percent. Hospitals and trauma centres accounted for over 48 percent of devices; clinics 32 percent; neurosurgery centres 20 percent. Wireless micro‑sensor adoption reached approx 45 percent of hospital installs in 2024. European countries reported unit installations exceeding 90,000 systems by end‑2024. Non‑invasive adoption in Europe ranged from 12–18 percent.

Europe’s ICP monitoring devices market is expected to be around USD 155.0 million in 2025 nearly 29% share of the global market and grow at a CAGR of 5.7%, supported by rising neuro ICU investments and aging demographics.

Europe – Major Dominant Countries in the “ICP Monitoring Devices Market”

• Germany: Germany will lead Europe with USD 48.0 million by 2034, holding 31% of regional market and a CAGR of 5.6% in neurocritical units.
• United Kingdom: The UK’s market is projected at USD 38.5 million by 2034, contributing 25% share and growing at 5.8% CAGR in trauma and stroke centers.
• France: France is expected to reach USD 27.8 million by 2034, accounting for 18% share with a CAGR of 5.5% due to hospital ICU upgrades.
• Italy: Italy’s ICP devices market is forecast at USD 21.4 million by 2034, capturing 13.8% share and growing at 5.7% CAGR.
• Spain: Spain is estimated to grow to USD 19.1 million by 2034, holding 12.3% European share and rising at 5.6% CAGR.

ASIA‑PACIFIC

Asia‑Pacific captured roughly 25 percent of global device units by 2024. China, India, Japan and South Korea led with approx unit shipments totalling 75,000 systems in 2023. Invasive devices held around 75 percent share of installed base; non‑invasive reached 7 percent share of units by 2024. Traumatic Brain Injury applications accounted for 40 percent; hemorrhage 22 percent; others 38 percent. Hospitals and trauma centres represented 52 percent of installations; clinics 28 percent; neurosurgery centres 20 percent. Wireless micro‑sensor systems accounted for approximately 40 percent of hospital installations. Non‑invasive uptake in Asia‑Pacific was around 7 percent in 2024. Population growth and rising neurological disorder incidence fuel unit demand.

Asia is expected to hold approximately USD 105.0 million in 2025 (about 19.7% global share) and grow at a CAGR of 6.0% by 2034, driven by expansion in neurocritical services across emerging markets.

Asia – Major Dominant Countries in the “ICP Monitoring Devices Market”

• India: India’s ICP device market will reach USD 64.0 million by 2034, holding 41% of Asia’s share, growing at 6.3% CAGR with expanding clinical infrastructure.
• Japan: Japan is projected to reach USD 35.5 million by 2034, contributing 22.6% share and growing at 5.5% CAGR due to stroke and neurosurgery focus.
• China: China will account for USD 32.2 million by 2034, representing 19.5% share with a 6.1% CAGR amid rising neurotrauma incidence.
• South Korea: South Korea’s market is expected at USD 22.5 million by 2034, with 14.4% regional share and growing at 5.8% CAGR in intensive care units.
• Australia: Australia is forecast to reach USD 23.8 million by 2034, holding 15.3% share and expanding at 5.4% CAGR due to hospital modernization.

MIDDLE EAST & AFRICA

Region held about 7 percent of global device units as of 2024. South Africa represented the largest share within the region. Invasive devices made up approximately 85 percent of installations; non‑invasive 15 percent. Traumatic Brain Injury applications accounted for 35 percent ; hemorrhage 20 percent ; others 45 percent. Hospitals and trauma centres captured 50 percent of installations; clinics 30 percent; neurosurgery centres 20 percent. Wireless micro‑sensor adoption stood near 30 percent of hospital installations in 2024. Stroke incidence in Saudi Arabia and South Africa rising, driving demand for ICP systems. Non‑invasive share in the region ranged from 10–15 percent of units.

Middle East & Africa's ICP monitoring devices market is estimated at USD 43.0 million in 2025 (8.1% of global share) and is expected to grow at 5.3% CAGR through 2034, supported by growing neurocritical care adoption.

Middle East and Africa – Major Dominant Countries in the “ICP Monitoring Devices Market”

• Saudi Arabia: Saudi Arabia is set to reach USD 15.5 million by 2034, capturing 36% regional share and growing at 5.4% CAGR via national hospital upgrades.
• United Arab Emirates: The UAE is forecast to hold USD 12.2 million by 2034, making up 28.4% of regional market with a CAGR of 5.2%.
• South Africa: South Africa’s market will reach USD 7.8 million by 2034, a 18.1% regional share with a CAGR of 5.0% driven by expanding private hospitals.
• Egypt: Egypt is projected at USD 5.6 million by 2034, with a 13.0% share and growing at 5.3% CAGR in neuro ICU expansion.
• Nigeria: Nigeria’s market is expected to reach USD 2.9 million by 2034, holding 6.7% regional share and growing at 5.1% CAGR amid rising trauma care services.

List of Top Intracranial Pressure (ICP) Monitoring Devices Companies

• Medtronic
• Johnson & Johnson
• HeadSense Medical
• Raumedic
• Vittamed
• HaiWeiKang
• Spiegelberg
• Integra LifeSciences
• Sophysa Ltd

Medtronic: accounted for approximately 25–30 percent of global device unit share in 2024, recognized as top company in the Intracranial Pressure (ICP) Monitoring Devices Market Share category.

Integra LifeSciences: represented roughly 20–25 percent of global unit installations in 2024, ranking as second‑largest company in sector Market Share (both numbers illustrate factual prominence).

Investment Analysis and Opportunities

Investment in the Intracranial Pressure (ICP) Monitoring Devices Market focuses on scaling minimally invasive systems and wireless sensor platforms, with over 51 percent of hospital unit installs in 2024 already using such technologies. Asia‑Pacific non‑invasive device share rose to 7 percent, signaling investment potential. Hospitals still account for more than 50 percent of installations globally, clinics 30 percent, neurosurgery centres 20 percent representing B2B purchaser categories. Opportunities include increased deployment in trauma centres where TBI incidence exceeds 1,000,000 annually in the U.S., stroke events 795,000 per year, and hydrocephalus/migraine cohorts (35 million migraine sufferers in U.S.) underscoring unit demand. Wireless telesensor cases (136 patients study) yielded savings of £5236 per patient via reduced radiographic encounters and inpatient neurosurgical admissions. 

New Product Development

New product development in the Intracranial Pressure (ICP) Monitoring Devices Market centers on innovation in wireless micro‑sensors, predictive analytics integration, and telesensor telemonitoring. In 2024, wireless micro‑sensor systems made up over 51 percent of hospital unit installations. Predictive analytics platforms delivered pressure prediction accuracy within ≤ 1.0 mm Hg in over 75 percent of deployments. Integra LifeSciences relaunched its CereLink ICP Monitoring System in April 2024, offering MR conditional sensors, minimal drift over multi‑day use, flexible probe design, and enhanced data presentation features. Luciole Medical (via Spiegelberg acquisition in June 2023) strengthened its invasive catheter design, capturing part of the 94.2 percent invasive segment projection by 2037. Telesensor systems studied in a 136‑patient cohort reduced neurosurgical inpatient admissions and radiographic encounters by 30 percent, saving £5236 per patient. 

Five Recent Developments

• In June 2023, Luciole Medical AG acquired Spiegelberg GmbH, expanding invasive ICP catheter device portfolio, aligning with projected 94.2 percent invasive unit share by 2037.
• In December 2022, Natus Medical Incorporated acquired Micromed Holding SAS, enhancing accessory and monitoring systems across 80 percent of application units.
• In April 2024, Integra LifeSciences relaunched its CereLink ICP Monitoring System in the U.S., featuring MR‑conditional sensors, reduced drift, and advanced display for hospital installations.
• In 2024, wireless micro‑sensor installations surpassed 51 percent of hospital units globally, with predictive analytics delivering ≤ 0 mm Hg accuracy in over 75 percent of cases.
• In a 2024 telesensor study of 136 patients (73 telesensors vs 63 controls), cumulative savings after 2 years reached approx £5236 per patient, with radiographic encounters and neurosurgical admissions reduced by 30 percent.

Report Coverage of Intracranial Pressure (ICP) Monitoring Devices Market

The Intracranial Pressure (ICP) Monitoring Devices Market Research Report offers detailed coverage of industry dynamics, key segments, regional outlook, competitive landscape, recent developments and product innovation. It includes unit shipment and installed base data e.g. about 310,000 device units shipped in 2023, 285,000 installed systems by end‑2024, invasive share 80–94 percent, non‑invasive 6–20 percent. The report outlines segmentation by technique (invasive, non‑invasive) with detailed shares (invasive 82 percent, non‑invasive 18 percent in Europe, similar ratios globally), by application (TBI 38 percent, ICH + SAH 25 percent, others 37 percent) and by end‑user (hospitals 50 percent, clinics 30 percent, neurosurgery centres 20 percent). Regional coverage includes North America (38 percent of units globally, U.S. 95 percent of NA), Europe (30 percent), Asia‑Pacific (25 percent), Middle East & Africa (7 percent). It reviews top players unit share estimates (Medtronic 25–30 percent, Integra 20–25 percent) and recent manufacturer strategic actions (Luciole‑Spiegelberg, Integra relaunch, acquisition deals).

Intracranial Pressure (ICP) Monitoring Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 564.56 Million in 2026
Market Size Value By	USD 944.38 Million by 2035
Growth Rate	CAGR of 5.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Invasive ICP Devices Non-invasive ICP Devices By Application : Traumatic Brain Injury Intracerebral Hemorrhage Meningitis Subarachnoid Hemorrhage Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample